valproic acid has been researched along with Cardiac Hypertrophy in 5 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Another set of rats were treated with hydralazine (25 mg/kg per day orally) to determine the pressure-independent effects of HDAC inhibition on hypertension." | 3.76 | HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. ( Cardinale, JP; Elks, CM; Francis, J; Guggilam, A; Mariappan, N; Pariaut, R; Sriramula, S, 2010) |
| "Valproic acid has been shown to upregulate estrogen receptors (ERs) in breast and prostate cancer tissues." | 1.48 | Magnesium valproate ameliorates type 1 diabetes and cardiomyopathy in diabetic rats through estrogen receptors. ( Bhadada, S; Dudhrejiya, A; Patel, B; Rabadiya, S; Vaishnav, D, 2018) |
| "The regulatory paradigm in cardiac hypertrophy involves alterations in gene expression that is mediated by chromatin remodeling." | 1.46 | Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy. ( Goyal, RK; Patel, BM; Raghunathan, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rabadiya, S | 1 |
| Bhadada, S | 1 |
| Dudhrejiya, A | 1 |
| Vaishnav, D | 1 |
| Patel, B | 1 |
| Kee, HJ | 1 |
| Bae, EH | 1 |
| Park, S | 1 |
| Lee, KE | 1 |
| Suh, SH | 1 |
| Kim, SW | 1 |
| Jeong, MH | 1 |
| Raghunathan, S | 1 |
| Goyal, RK | 1 |
| Patel, BM | 1 |
| Cardinale, JP | 1 |
| Sriramula, S | 1 |
| Pariaut, R | 1 |
| Guggilam, A | 1 |
| Mariappan, N | 1 |
| Elks, CM | 1 |
| Francis, J | 1 |
| Lee, TM | 1 |
| Lin, MS | 1 |
| Chang, NC | 1 |
5 other studies available for valproic acid and Cardiac Hypertrophy
| Article | Year |
|---|---|
Magnesium valproate ameliorates type 1 diabetes and cardiomyopathy in diabetic rats through estrogen receptors.
Topics: Animals; Cardiomegaly; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Cardiomy | 2018 |
HDAC inhibition suppresses cardiac hypertrophy and fibrosis in DOCA-salt hypertensive rats via regulation of HDAC6/HDAC8 enzyme activity.
Topics: Animals; Cardiomegaly; Desoxycorticosterone Acetate; Disease Models, Animal; Enzyme Activation; Fibr | 2013 |
Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy.
Topics: Animals; Biomarkers; Cardiomegaly; Disease Models, Animal; DNA, Mitochondrial; Down-Regulation; Fema | 2017 |
HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Echocardiography; Histone Deacetylas | 2010 |
Inhibition of histone deacetylase on ventricular remodeling in infarcted rats.
Topics: Animals; Atrial Natriuretic Factor; Blotting, Western; Cardiomegaly; Cell Size; Collagen; Coronary V | 2007 |